Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.
breast cancer
fluorescent multiplex immunohistochemistry
tertiary lymphoid structure
tumor immune microenvironment
tumor-infiltrating lymphocytes
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
02
2021
accepted:
11
08
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
9
10
2021
Statut:
epublish
Résumé
Our expanding knowledge of the interactions between tumor cells and their microenvironment has helped to revolutionize cancer treatments, including the more recent development of immunotherapies. Immune cells are an important component of the tumor microenvironment that influence progression and treatment responses, particularly to the new immunotherapies. Technological advances that help to decipher the complexity and diversity of the tumor immune microenvironment (TIME) are increasingly used in translational research and biomarker studies. Current techniques that facilitate TIME evaluation include flow cytometry, multiplex bead-based immunoassays, chromogenic immunohistochemistry (IHC), fluorescent multiplex IHC, immunofluorescence, and spatial transcriptomics. This article offers an overview of our representative data, discusses the application of each approach to studies of the TIME, including their advantages and challenges, and reviews the potential clinical applications. Flow cytometry and chromogenic and fluorescent multiplex IHC were used to immune profile a HER2+ breast cancer, illustrating some points. Spatial transcriptomic analysis of a luminal B breast tumor demonstrated that important additional insight can be gained from this new technique. Finally, the development of a multiplex panel to identify proliferating B cells, Tfh, and Tfr cells on the same tissue section demonstrates their co-localization in tertiary lymphoid structures.
Identifiants
pubmed: 34621785
doi: 10.3389/fmolb.2021.673042
pii: 673042
pmc: PMC8490683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
673042Informations de copyright
Copyright © 2021 Boisson, Noël, Saiselet, Rodrigues-Vitória, Thomas, Fontsa, Sofronii, Naveaux, Duvillier, Craciun, Larsimont, Awada, Detours, Willard-Gallo and Garaud.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Histochem Cytochem. 2009 Oct;57(10):899-905
pubmed: 19365090
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Sci Immunol. 2016 Jul 14;1(1):aaf6925
pubmed: 28783673
Front Immunol. 2019 Sep 20;10:2155
pubmed: 31616408
J Vis Exp. 2019 Jan 21;(143):
pubmed: 30735177
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Front Immunol. 2017 Oct 30;8:1412
pubmed: 29163490
Front Immunol. 2020 Sep 02;11:1842
pubmed: 32983100
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564
pubmed: 32303794
Methods Mol Biol. 2015;1318:161-72
pubmed: 26160574
Science. 2016 Jul 1;353(6294):78-82
pubmed: 27365449
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Science. 2019 Mar 29;363(6434):1463-1467
pubmed: 30923225
Oncoimmunology. 2016 Dec 14;6(1):e1257452
pubmed: 28197375
Methods Enzymol. 2020;635:1-20
pubmed: 32122539
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Mod Pathol. 2017 Sep;30(9):1204-1212
pubmed: 28621322
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Breast Care (Basel). 2019 Apr;14(2):103-110
pubmed: 31798382
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Front Immunol. 2018 Nov 20;9:2660
pubmed: 30515157
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Ann Oncol. 2015 Aug;26(8):1698-704
pubmed: 25995301
Front Immunol. 2017 Mar 16;8:293
pubmed: 28360915
Nat Rev Cancer. 2020 Oct;20(10):594-607
pubmed: 32678342
Sci Rep. 2021 May 31;11(1):11359
pubmed: 34059727
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
J Vis Exp. 2014 Dec 06;(94):
pubmed: 25548995
Immunity. 2018 Aug 21;49(2):264-274.e4
pubmed: 30076099
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Immunol Rev. 2020 Nov;298(1):153-164
pubmed: 32691450
Br J Cancer. 2020 Aug;123(4):624-632
pubmed: 32451467
J Clin Invest. 2021 Oct 1;131(19):
pubmed: 34411002
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
J Med Virol. 2020 Jan;92(1):62-70
pubmed: 31475733
Nat Methods. 2019 Oct;16(10):987-990
pubmed: 31501547